Kura Oncology (KURA) Assets Average (2011 - 2026)
Kura Oncology (KURA) posted quarterly Assets Average of $695.5 million for Q1 2026, down 7.51% year-over-year from $752.0 million in Q1 2025, and little changed quarter-over-quarter from $693.9 million in Q4 2025.
Kura Oncology (KURA) Assets Average (2011 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Assets Average for 16 consecutive years, with $695.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 7.51% year-over-year to $695.5 million; the TTM figure through Mar 2026 stood at $695.5 million (down 7.51% YoY), while the FY2025 annual figure was $749.3 million, up 23.94% from the prior year.
- Assets Average held at $695.5 million in Q1 2026 per KURA's latest filing, from $693.9 million in the prior quarter.
- Across five years, Assets Average topped out at $752.0 million in Q1 2025 and bottomed at $441.1 million in Q1 2023.
- Historically, Assets Average has averaged $554.9 million across 5 years, with a median of $501.4 million in 2024.
- Annual changes were most pronounced in 2022 — Assets Average retreated 19.77% — and 2025, when it jumped 49.97%.
- Kura Oncology's Assets Average stood at $452.1 million in 2022, then rose by 2.04% to $461.4 million in 2023, then surged by 34.28% to $619.5 million in 2024, then advanced by 12.01% to $693.9 million in 2025, then gained by 0.23% to $695.5 million in 2026.
- Business Quant data shows KURA's Assets Average at $695.5 million in Q1 2026, $693.9 million in Q4 2025, and $665.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 620.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 620.17 Mn |
| Mar 31, 2026 | 695.46 Mn |
| Dec 31, 2025 | 693.87 Mn |
| Sep 30, 2025 | 665.90 Mn |
| Jun 30, 2025 | 713.09 Mn |
| Mar 31, 2025 | 751.96 Mn |
| Dec 31, 2024 | 619.50 Mn |
| Sep 30, 2024 | 496.98 Mn |
| Jun 30, 2024 | 534.51 Mn |
| Mar 31, 2024 | 501.42 Mn |
| Dec 31, 2023 | 461.35 Mn |
| Sep 30, 2023 | 484.25 Mn |
| Jun 30, 2023 | 460.36 Mn |
| Mar 31, 2023 | 441.14 Mn |
| Dec 31, 2022 | 452.15 Mn |
| Sep 30, 2022 | 459.71 Mn |
| Jun 30, 2022 | 485.01 Mn |
| Mar 31, 2022 | 516.32 Mn |
| Dec 31, 2021 | 547.60 Mn |
| Sep 30, 2021 | 573.02 Mn |